Colombian health minister Alejandro Gaviria has announced, during the Andi Pharmaceutical Forum held in the city of Cartagena, that the negotiations with Swiss pharmaceutical giant Novartis over their pricing of cancer drug Glivec had come to an unsuccessful end. With negotiations breaking down, the chance for a bilateral agreement has been scuppered, and the government will now unilaterally set the market price for the drug.
The next step will involve declaring the the active molecule Imatinib to be a matter of public interest, which would allow for the government to request an official administrative procedure to set a fair price for the drug.
The initiative by the Health ministry has been widely backed by Colombia’s various forces, as the government tries to pry away the monopoly over the active ingredient from Novartis. The aim is to allow for local laboratories to produce competing products, which would lower prices and give patients better access to the drug.
Full Content: Entorno Inteligente
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI